ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$233.29
+0.63%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$232.43
From 52W high−52.51%
Volume1.34M
Market cap$31.22B
P/E (TTM)38.2x
P/S (TTM)6.5x
Div yield—
Key dataOct 19, 2026
Open
$232.43
From 52W high
−52.51%
Volume
1.34M
Market cap
$31.22B
ValuationView details →
P/E (Fwd)
25.6x
EV/EBITDA
25.4x
P/E (TTM)
38.2x
RSI (14)
48.9
MomentumView details →
1D Return
+0.63%
YTD Return
−41.05%
SummaryUpdated Jun 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.53d agoAlnylam Pharmaceuticals announced it will present new clinical and real-world data across its ATTR and hypertension programs at the ESC Congress 2026 in Munich, Germany, from August 28-31, 2026.57d ago